A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors
A Pilot Study of Using [18F]F AraG PET Imaging to Evaluate the Immunological Response to Checkpoint Inhibitor Therapy (CkIT) in Patients With Advanced Solid Tumors
This study is testing if a special imaging technique can help doctors see how well checkpoint inhibitor therapy works for people with solid tumors.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | CellSight Technologies, Inc. Industry-sponsored |
| Locations | 2 sites (Stanford, California and 1 other locations) |
| Trial ID | NCT04260256 on ClinicalTrials.gov |
What this trial studies
Processing failed - manual review needed
Who should consider this trial
Good fit: Unknown
Not a fit: Unknown
Why it matters
Potential benefit: Unknown
How similar studies have performed: Unknown
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Solid tumor with planned CkIT * Must be \>18 years old * Signed Informed Consent Form * Patient must have two qualifying lesions Exclusion Criteria: * Patient is pregnant or breast feeding
Where this trial is running
Stanford, California and 1 other locations
- Stanford University — Stanford, California, United States (Recruiting)
- Oregon Health and Science University — Portland, Oregon, United States (Recruiting)
Study contacts
- Principal investigator: Carina Mari Aparici, M.D. — Stanford University
- Study coordinator: LIbby Mirande
- Email: jenselib@ohsu.edu
- Phone: 503 494 4740
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-06-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.